Ann: Proteomics raises $3m in heavily oversubscribed Placement, page-29

I agree @ddzx, and that Janssen data will be what is necessary here for a CDx. The FDA won’t hold this up when a drug is approved already for clinically unmet needs (CKD) & proof via clinical trials is evident of efficacy in testing (CDx), plus validation from independent clinical trials (excluding Janssen CREDENCE trial for SLGT2 class, Invokana). We already have CE approval in the EU. I think they are going for the “BIG ONE” in the USA with FDA & Janssen collaboration.

Not going to be impatient with these processes in biotechs, or you shoot yourself in the foot. IMO DYOR